Install
OncoDaily is a specialized oncology news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest developments in the f
- 818articles · 30d
- 28+ min agolatest article
- Aug 14, 2026earliest in window
- 10%with images · 19 videos
- 187avg words
- Health & Wellness 791
- Medical 756
- Health 749
- Education & Jobs 40
- Human Interest 25
- Science & Technology 18
- Education 15
- Economy, Business & Finance 6
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Miguel Bronchud: A New Molecular Switch in Prostate Cancer Treatment Resistance
1+ hour, 30+ min ago (480+ words) “Prostate cancers – ‘maybe lost in translation’? New hopes for more effective treatments ‘This is the first time anyone’s ever shown that the identity of the cell can be regulated by inhibiting translation’ said at the Fred Hutch Institute in Seattle…...
Shilpa Gupta: ARON’s Growth Into a Global GU Cancer Research Network - OncoDaily
1+ hour, 52+ min ago (115+ words) Shilpa Gupta, Director of Genitourinary Medical Oncology at Taussig Cancer Institute, Cleveland Clinic, shared on LinkedIn: “Deeply honored to be the keynote speaker and ARON award recipient at the ARON meeting for the commitment to making ARON a global research…...
Dactinomycin: Mechanism of Action, Dose, Administration, Clinical Uses, and Side Effects - Oncology News, Insights, Stories by OncoDaily
2+ day, 18+ hour ago (633+ words) Discussions Around the DeLLphi-305 Trial FDA Expands Accelerated Approval of Sevabertinib for HER2-Mutant Non-small Cell Lung Cancer Vanessa Kerry։ Honored to Have Been Appointed as the Director-General's Special Envoy for Health Resilience Hodgkin Lymphoma in 2026: What the New EHA Guidelines…...
Yuliya Byakina: Happy to Start a New Position at Johnson & Johnson Innovative Medicine - OncoDaily
5+ day, 57+ min ago (74+ words) Yuliya Byakina: Happy to Start a New Position at Johnson & Johnson Innovative Medicine Oncodaily Yuliya Byakina, Sr. Medical Science Liaison – (Hematology/ Multiple Myeloma) OR/ID at Johnson & Johnson Innovative Medicine, shared on LinkedIn: “I’m happy to share that I’m starting…...
Merck and Moderna Announce Positive Phase 3 Results for Intismeran Autogene Plus Pembrolizumab in High-Risk Melanoma - The Babak Lab - OncoDaily
5+ day, 1+ hour ago (88+ words) The Babak Lab shared on LinkedIn: “Merck and Moderna have announced positive top-line results from the Phase 3 INTerpath-001 trial of intismeran autogene (V940) + pembrolizumab in patients with resected high-risk melanoma. INTerpath-001 is the first positive Phase 3 trial of an individualized neoantigen…...
Megan Melody: Sequencing CD19-Targeted Therapies in Large B-Cell Lymphoma - OncoDaily
5+ day, 3+ hour ago (125+ words) Megan Melody: Sequencing CD19-Targeted Therapies in Large B-Cell Lymphoma / B-cell, Blood Reviews, cancer, Gloria Iacoboni, Large B-Cell Lymphoma, lymphoma,, B-cell, Blood Reviews, cancer, Gloria Iacoboni, Large B-Cell Lymphoma, lymphoma, Manali Kamdar, Megan Melody, Mehdi Hamadani, OncoDaily, Oncology, Paolo F. Caimi, Romano…...
Jason Mouabbi: Fantastic News for Breast Cancer Patients as FDA Approves Camizestrant
1+ week, 3+ hour ago (80+ words) Jason Mouabbi, Assistant Professor at MD Anderson Cancer Center, shared on LinkedIn: FDA accelerated approval: camizestrant + CDK4/6i at ESR1 emergence on 1L AI + CDK4/6i (SERENA-6). mPFS 16.0 vs 9.2 mo, HR 0.44. First approval ever driven by ctDNA, not imaging. Molecular progression is now actionable in the…...
Sandrine Piret-Gerard: Argenx Seeks New Talent to Drive Innovation in Immunology - OncoDaily
1+ week, 9+ hour ago (160+ words) Sandrine Piret-Gerard, Chief Commercialization Officer (CCO) at argenx, shared Jeff Kennedy’s, Head of Human Resources, US Commercialization at argenx, on LinkedIn, adding: “One of the things I’m most excited about argenx is how quickly we’re growing while staying true to…...
Hannah Levy: Rethinking CAR-T and the Future of B-Cell Lymphoma Care
1+ week, 9+ hour ago (175+ words) Hannah Levy, Scientific Intelligence Analyst and Global Moderator at MedNews Week, shared MedNews Week’s post on LinkedIn, adding: “Not every day you get to see yourself turned into a comic! Such a fun way to revisit this conversation with Dr....
Marco Donia: Real-World Data Show an OS Benefit With Adjuvant Anti-PD-1 in Stage III Melanoma - OncoDaily
1+ week, 22+ hour ago (219+ words) Marco Donia, Professor at CCIT-DK, shared by Marie Weitemeyer, PhD Fellow at Copenhagen University Hospital, on LinkedIn. “A small but real OS advantage in patients with resected stage III melanoma, treated with adjuvant anti-PD1 (note however all the limitations of…...